Skip to content
NBlaz – Lifestyle
Author:
Herantis Pharma plc
Horizon Europe-funded HERMOD project launches to support Phase 2 development of HER-096 in Parkinson’s disease
November 11, 2026
Herantis Pharma: newly published clinical evidence validates HER-096 Phase 2 study design
November 5, 2026
Herantis Pharma releases 1H 2026 report today
August 20, 2026
Herantis appoints experienced drug development expert Dr Juha Savola as Chief Medical Officer
June 25, 2026
Herantis reports positive FDA feedback and finalizes Phase 2a study design for HER-096
June 2, 2026
Herantis Pharma partners with Indivi to enable detection of early treatment effects in upcoming HER-096 Phase 2 trial in Parkinson’s disease
May 19, 2026